Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-06-05-Speech-4-022"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-06-05"^^xsd:date2
dcterms:Is Part Of	lp_eu:Breast cancer2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20030605.1.4-022"2
lpv:hasSubsequent	lp_eu:2003-06-05-Speech-4-0232
lpv:speaker	lp:Nelly Maes2
lpv:spokenAs	vice-chair; G/EFA (2002-01-08--2004-07-19)3 unknown; België Spirit (2002-01-08--2004-07-19)3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (2002-01-17--2004-07-19)3 substitute; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (2002-02-07--2004-04-30)3 member; Members from the European Parliament to the Joint Parliamentary Assembly of the Agreement between the African, Caribbean and Pacific States and the European Union (ACP-EU) (2002-02-06--2004-07-19)3 substitute; Committee on Development and Cooperation (2002-01-17--2004-07-19)3 member; Committee on Regional Policy, Transport and Tourism (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, Commissioner, on my last visit to the gynaecologist she told me that the risk in Belgium has risen from one woman in 10 to one woman in eight. These are frightening statistics and I think that the drama of discovering breast cancer in a woman is still a major trauma for herself and her family, even though this cancer can often be cured if discovered early on. One in eight, though, is too high a risk and in Belgium we are in fourth place behind the Netherlands, Denmark and France. We must also take into account that there are unacceptably large differences in the chances of survival, depending on whether you live in one country or another. Early detection, diagnosis and treatment and aftercare help thousands of women to survive, but these chances of survival vary from 81% in France to 58% in Poland and Slovakia. That must make us think. The quality of the research must therefore be reliable and in this regard it concerns me that only eight countries are considering doing a general screening test. There are discussions about this. In Belgium they are baulking at the idea, on the one hand, because of the cost, but on the other I am sure that there is great pressure from the medical world to keep it to individual medical investigations by your own doctor. It would be good to examine the results of these different approaches critically in the light of what you, Commissioner, called cooperation in connection with knowledge gathering. There is a common European strategy, but there is a need to do more than prevention alone. I think that we need to do more research into the causes. Various fellow Members, Mrs Boogerd among them, have pointed out that there are still many unresearched areas. In particular I should like to bring Mrs Jöns’s recommendation in paragraph 11 to your attention and ask you to discuss it with your fellow Commissioner Mr Busquin, because the consequence of the patenting of genes could be that this monopoly unnecessarily stands in the way of breast cancer research."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph